biomedicine

Scientists at the Universitat Autònoma de Barcelona (UAB) have found that an alteration of a neuronal gene program plays an essential role in the first stages of Alzheimer's disease and have developed a gene therapy which is effective on mice. The Catalan study occupies the front page of 'The Journal of Neuroscience'. Researchers have identified a new mechanism that regulates the expression of genes in the brain which are essential for the function of neuronal circuits involved in learning and memory. According to the new study, which was carried out by Dr. Carlos Saura's group at the UAB's Institute of Neurosciences (Institut de Neurociències), the alteration of a gene program mediating neuronal transmission and survival may underlie memory loss at early pathological stages of Alzheimer's disease (AD).

Japanese multinational Olympus, specialized in optics and reprography, has unveiled its new headquarters for Spain and Portugal, aimed at becoming its main centre for Southern Europe. The new facilities are located in the business district of L'Hospitalet de Llobregat, a city literally attached to Barcelona, between the Catalan capital and El Prat Airport. The new offices occupy 2,500 square meters in a building on the Europa Square, close to the Fira de Barcelona. It will welcome 30 employees of the divisions of Consumer Product, Microscopy, Industry, and Medical Systems. Merging the headquarters for Spain and Portugal constitutes a step forward to gain weight on the Southern Europe market, said Olympus Iberia's CEO.

Barcelona’s Hospital Clínic has installed the ‘Micra’ 24mm pacemaker - equivalent to the size of a one euro coin -  in 4 patients as part of a clinical trial involving 10 medical centres and 60 patients troughout the world. This innovative wireless system is minimally invasive since it does not require any surgical procedure but is implanted in the heart through the femoral vein using a catheter. Such a procedure can be performed within 30 minutes and also reduces the patients’ risks of future infections. According to the Medical Director of the Hospital, Josep Brugada, if the clinical study is successful, it will involve a “paradigm shift”. Experts estimate it could reach hospitals within the next two or three years.

During the 2014 Innovation Convention, organised by the European Commission on Tuesday, Barcelona was named the first European Capital of Innovation. The Catalan capital has prevailed over finalists Grenoble (France) and Groningen (the Netherlands) in a contest which also involved Paris, Espoo (Finland) and Malaga (Spain). The winning project highlights the predominant role of the city in promoting new technologies and bringing together government bodies and citizens, in order to enhance sustainable economic growth and improve the people’s welfare. The award is endowed with € 500,000 to promote innovation. Barcelona's Mayor, Xavier Trias, stated that new technologies in an urban environment have to "work towards improving people's everyday lives[…] or they will fail".

The Catalan Institute of Nanoscience and Nanotechnology (ICN2) has set up its new headquarters at the Universitat Autònoma de Barcelona (UAB) campus. The new faculties are located in a 6,000 square meter building with 40 laboratories, where scientific projects will be developed in different areas, from biomedicine to the development of everyday products such as paint or detergents.. This project is funded by both the Catalan and Spanish Governments and aims to make the centre a flagship in the European scientific field.

A surgical team of the Hospital de Bellvitge in L’Hospitalet de Llobregat, Greater Barcelona, has successfully reconstructed the breasts of 22 women suffering from cancer in one single surgery. This world pioneer medical procedure, consisting in transplanting dorsal muscle on to the removed breast, allows patients to “turn the page” on the disease much more quickly, according to Joan Maria Vinyals, the Head of plastic surgery. Indeed, this “complete and radical reconstruction”, which includes the nipple and areola, avoids having to proceed to a second surgery and erases the usual trauma regarding aesthetic concerns. Leonor Garrido, one of the patients, stated that the technique “had improved a lot” her quality of life since she had her tumour removed and the breast entirely reconstructed immediatly after.

A clinical trial conducted in nine Catalan health care centres and published in the ‘British Medical Journal’ found that “in the case of mild respiratory infections such as acute bronchitis, there is a misuse of antibiotics, which is of no benefit to patients, and only helps increasing resistance to these drugs”. The study has been coordinated by the prestigious Vall d’Hebron Research Institute (VHIR). From 2010 to 2012, 416 patients, who showed several signs of acute bronchitis, were randomly assigned one of three different treatments. The main conclusion was that antibiotics, the most widely prescribed treatment for this type of illness, are ineffective. The study also showed that anti-inflammatory treatments increased in a minimal way the chances of ending coughs faster.

Referring to yesterday’s announcement, Carles Constante, the Director General for Regulation, Planning and Health Resources at the Catalan Ministry of Health, said that the Director of Barcelona’s Centre for Regenerative Medicine (CMRB), Juan Carlos Izpisúa had resigned due to the need for a more direct management. Constante explained that even though research centres now had a “high level of interconnection and ongoing dialogue”, they also needed “direction, management and a drive of energy within the centre itself, something that could be difficult to maintain from a distance”. Constante stressed that Izpisúa working from the United States for most of the time had been the main reason for him stepping down.

The Director of Barcelona’s Centre for Regenerative Medicine (CMRB), world-famous scientist Juan Carlos Izpisúa, resigned due to the lack of financial and political support from both Spanish and Catalan Governments. Such news was first published by Spanish newspaper ‘El País’ and then confirmed by sources in the research centre. Internationally, Izpisúa is considered to be one of the most esteemed and learned scientists in the field of stem cells. With the Director stepping down, the CMRB could well lose most of its current projects. Indeed, 18 of the 21 projects are the intellectual property of Izpisúa and might no longer be carried out in the Barcelona-based research centre if Izpisúa quit.

People who follow a Mediterranean diet enriched with extra virgin olive oil will reduce by 40% the risk of having diabetes, and by 18% if the diet is enriched with nuts. This is one of the main conclusions of a scientific study conducted by 18 research centres throughout Spain on 3,500 people. Jordi Salas-Salvadó, Director of this study, said that such results would change the usual perception of diabetes prevention. The Mediterranean diet is not solely efficient against diabetes. Indeed, the results showed that following such a diet also reduced by 30% the chances of contracting cardiovascular diseases.

The Catalan pharmaceutical company Grífols and Barcelona’s Alzheimer Treatment&Research Center of Fundació ACE – a family charity – have announced that they will run tests of a vaccine against this neurodegenerative illness from January 2014. It will target 365 Alzheimer’s patients at mild and moderate stages of the illness. The first investigation project that ACE’s centre will host is called Ambar. The 365 participants will be randomly divided into three treatment groups plus a fourth control group. The patients will come from 17 Spanish hospitals and 20 United States’ medical centres. From 1996, the ACE Foundation has evaluated more than 14,000 people, 47% of whom were diagnosed with Alzheimer’s. It has the largest bank of genetic data in Europe.

Biocat, the organisation responsible for coordinating and promoting the life sciences sector in Catalonia, presented the 2013 Biocat report in Barcelona. Since its creation in 2006, by the Catalan Government and the Barcelona City Council, Biocat has sought to consolidate the life sciences sector by bringing together researchers, companies and other professionals in the field of biotechnology and biomedecine from Catalonia and other countries in the world. With 65 % of its biotechnology, pharmaceutical and medical products sold on the international market, the Catalan ‘Bioregion’(biocluster) is amongst the leaders in the sector. The cluster is currently made of 512 companies, meaning twice as many as in 2000, 56 research centers dedicated to life sciences or related disciplines, 17 university hospitals and 11 universities offering training in biosciences. It also relies on numerous other technology poles. This year’s report stressed the significant increase in private funding for the Catalan BioRegion over the last 4 years (€ 5.7 million to € 25.6 million) while highlighting the drop in public aid.

Doctor Joan Massagué has been appointed Scientific Director of the Sloan-Kettering Institute in New York , the world’s leading cancer research centre, which is part of the Memorial Sloan-Kettering Cancer Centre. The Catalan scientist has been chosen by an international expert committee and will take office on the 1^st of January 2014. The President and CEO of the Memorial Sloan-Kettering, Craig B. Thomson, said that Massagué had been given the job for his “exemplarity as a scientist” and because he is an “international leader” in the study of metastasis and factors regulating cell growth. This announcement follows last year’s appointment of another Catalan Doctor, Josep Baselga, as the Physician-in-Chief of the Memorial Sloan-Kettering Cancer Centre. Both Baselga and Massagué will continue to combine their responsibilities in New York with their research in Barcelona.

Researchers from Barcelona’s Centre for Regenerative Medicine (CMRB), the Catalan capital’s Hospital Clínic and the Salk Institute of California have successfully created three-dimensional renal structures which are virtually indistinguishable from embryonic kidneys. They have started creating kidney cells from human stem cells, and ultimately proven that these newly created cells could aggregate in vitro to form a “micro-kidney”. The team led by Juan Carlos Izpisúa, from the CMRB, said that this scientific breakthrough would facilitate the study of kidney diseases and enable scientists to work on new treatments. He added that this achievement was a great step towards developing therapies based on the use of stem cells.

Researchers of Barcelona-based Vall d’Hebron Hospital and Research Institute discovered some of the main causes of the Idiopathic Pulmonary Fibrosis, which were unknown before today. Vall d’Hebron’s study showed that a continuous exposure to feather pillows and duvets was one of the main causes of this illness as it favours the scarring of lung tissue. This disease provokes a progressive decline of lung function and leads to asphyxia because of the deterioration of the organ’s tissue. The study has been able to trace the diseases’ causes in half of the studied cases. Besides feather pillows and duvets, the persistent exposure to fungus and close contact with birds can also trigger the illness. The Catalan research allows for a new approach to the illness’ prevention and its diagnosis in the early stages. It also represents a completely new approach to this pathology in terms of treatment.